Market Place
Sourcing Support
Lupin Divests US Women`s Health Specialty Business To Evofem
15 Jul 2024 //
PR NEWSWIRE
Lupin divests women’s health specialty business in US to Evofem for $84 million
15 Jul 2024 //
MONEY CONTROL
Lupin’s Solosec bags FDA approval for bacterial vaginosis and trichomoniasis
18 Feb 2022 //
PHARMABIZ
Lupin Signs Promotional Agreement with Exeltis on SOLOSEC
27 Jan 2022 //
PRNEWSWIRE
Lupin gets USFDA approval of sNDA for SOLOSEC (secnidazole)
09 Jul 2021 //
EXPRESS PHARMA
Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC
01 Jul 2021 //
PR NEWSWIRE
Lupin Announces Partnership with Phil, Inc. in Support of SOLOSEC® (secnidazole)
01 Feb 2021 //
PRNEWSWIRE
Lupin Announces FDA Filing Acceptance of Supplemental NDA for Solosec®
16 Nov 2020 //
BIOSPACE
Lupin Presents Phase 3 Data for Solosec® (secnidazole) Demonstrating Significant
13 Aug 2020 //
PRNEWSWIRE
Lupin Signs Marketing Agreement With Ceek for Women`s Health Products
09 Jun 2020 //
PRNEWSWIRE
Lupin Announces SOLOSEC® (secnidazole) Achievement of Preferred Status
22 Apr 2020 //
PR NEWSWIRE
Symbiomix Therap. Announces FDA`s Acceptance of New Drug Application for Solosec
23 Mar 2017 //
PR NEWSWIRE
Symbiomix Submits New Drug Application to US FDA
24 Jan 2017 //
DRUG DEVELOPMENT
Suspended lots of company drugs Prati Donaduzzi
04 Nov 2015 //
ANVISA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.